Seroconversion and Adverse Events for Gaucher Patients Treated With Alglucerase
| Total no. of patients with serum sample tested | 1,430 |
| Patients with at least one serum sample beyond baseline | 1,122 |
| No. of patients seroconverted while on therapy | 142 |
| % of seroconverted patients | 12.65 |
| No. of patients with reported adverse events | 74 |
| No. of seroconverted patients with reported adverse events | 34 |
| Total no. of patients with serum sample tested | 1,430 |
| Patients with at least one serum sample beyond baseline | 1,122 |
| No. of patients seroconverted while on therapy | 142 |
| % of seroconverted patients | 12.65 |
| No. of patients with reported adverse events | 74 |
| No. of seroconverted patients with reported adverse events | 34 |
Immunosurveillance of Gaucher patients treated with alglucerase. Summary of occurrence of seroconversion and immune-mediated adverse events of patients evaluated.